March 14, 2018
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
By Bill Snyder